
Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial
Key Takeaway:
Intravitreal photoswitch therapy, currently in early trials, shows promise in safely improving light response for patients with advanced retinitis pigmentosa.
For Clinicians:
"Phase 1 trial (n=12) of intravitreal photoswitch therapy in advanced retinitis pigmentosa. Safe with preliminary light response. Small sample, no control group. Await further trials before considering clinical application."
For Everyone Else:
This early research shows promise for retinitis pigmentosa, but it's not yet available in clinics. It may take years before it's ready. Continue with your current care and consult your doctor for advice.
Citation:
Nature Medicine - AI Section, 2026. DOI: s41591-026-04317-6 Read article →
